What's Happening?
A new review published in Frontiers in Veterinary Science details the complexities of adapting mRNA vaccine technology for animal use, contrasting it with its success in human medicine. The review indicates that much of the current understanding of mRNA vaccines
at a molecular level stems from human studies, leaving gaps in knowledge regarding their behavior in various animal species like cows or pigs. Key challenges include inefficient delivery, with only an estimated 1% to 2% of mRNA reaching the cell's cytosol, and species-specific immune responses that are not proportional to human or rodent data. Additionally, concerns arise regarding the distribution of vaccine particles in food-producing animals and the unknown fate of RNA vaccine residue in the environment. Despite these hurdles, milestones have been achieved, such as the approval of the first RNA-particle canine influenza vaccine in 2024 and conditional USDA approval for a poultry avian influenza vaccine in February 2025.
Why It's Important?
The adaptation of mRNA vaccine technology for animals holds significant implications for U.S. agriculture, veterinary medicine, and public health. Successful development could revolutionize disease prevention in livestock and companion animals, potentially reducing outbreaks of costly diseases like African swine fever or avian influenza, which have substantial economic impacts on the agricultural sector. Improved animal health through advanced vaccination could also enhance food security and reduce the need for antibiotics, addressing concerns about antimicrobial resistance. However, the challenges outlined in the review, particularly regarding food safety and environmental impact, must be thoroughly addressed to ensure consumer confidence and regulatory approval. The limited data on biodistribution and food safety in most veterinary species means that significant research and investment are still required before widespread adoption in food-producing animals.
What's Next?
Future efforts will likely focus on targeted research to understand species-specific immune responses and optimize mRNA delivery systems for various animal populations. This includes investigating how delivery particles clear from animal systems and how adaptive immune responses unfold in different livestock and companion animals. Addressing food safety concerns will necessitate comprehensive studies on the biodistribution of vaccine components in edible tissues and the establishment of appropriate withdrawal periods. Furthermore, research into the environmental fate of RNA vaccine residues in animal waste and slaughter waste will be crucial. The commercial landscape will likely see continued development and regulatory submissions for animal mRNA vaccines, building on the initial approvals for canine and poultry influenza vaccines, as companies seek to overcome the identified scientific and regulatory barriers.
Beyond the Headlines
The disparity in mRNA vaccine development between humans and animals highlights the complex interplay of scientific, economic, and ethical considerations in veterinary medicine. While human vaccine development often prioritizes individual health outcomes, animal vaccine development, especially for livestock, must also consider broader economic implications, food safety, and environmental impact. The review implicitly points to the need for more dedicated research funding and infrastructure for veterinary vaccinology, which often lags behind human medical research. The ethical dimension also emerges in discussions about animal welfare and the responsible use of advanced biotechnologies in food production. Overcoming these challenges could not only protect animal health but also contribute to a more sustainable and resilient agricultural system, potentially influencing global food supply chains and public health by reducing zoonotic disease risks.













